Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 155

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 155
---
 issuer. We intend to commence providing
such disclosure, at the latest, in the annual proxy statement for our first annual meeting of shareholders following the closing of this
offering, which will be filed under cover of a report on Form 6-K.

As
of December 31, 2024, options to purchase 37,500 Ordinary Shares granted to one of our directors were outstanding under our Option Plan
at an exercise price of $3.97 per share. The following table sets forth information regarding options granted to our executive officers
and directors during the year ended December 31, 2024:

| Name                |     | Grant          
 Date           |     | Stock   
 Options |        |     | Exercise 
 Price    |      |     | Expiration     
 Date           |
|:--------------------|:----|:---------------|:----|:--------|-------:|:----|:---------|-----:|:----|:---------------|
| Mr. Keith Valentine |     | September 2015 |     |         | 37,500 |     | $        | 3.97 |     | September 2025 |

As
approved by our board of directors, subject to and following the completion of this offering, we intend to grant options to purchase
up to 39,295 Ordinary Shares and up to 465,533 Ordinary Shares to Mr. Pini Ben-Elazar and Dr. Ehud Geller, respectively. The options
will have an exercise price of NIS 0.01 and will expire on the ten-year-anniversary of the grant date.

In
addition, on March 20, 2025, our shareholders approved a one-time payment to Mr. Ehud Geller in the amount of $500,000 in consideration
of his services to the Company since 2019, for which he has not received compensation. The payment is conditional upon the closing of
this offering. Subsequent to the shareholders’ approval of the payment, Mr. Geller agreed that $250,000 will be paid upon completion
of this offering and the remainder will be deferred until the Company completes a future fundraising.

Engagement Agreements with Executive Officers

We
have entered into written engagement or consultancy agreements with each of our executive officers, including our Chairman, Dr. Ehud
Geller and our Chief Executive officer, Dr. Eli Hazum. These agreements are terminable by either party upon 60 days’ prior written
notice. All of these agreements contain customary